DGAP-News: MagForce AG participates in four upcoming international conferences in Q4 2016


DGAP-News: MagForce AG / Key word(s): Conference
MagForce AG participates in four upcoming international conferences in Q4
2016

27.10.2016 / 08:30
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

MagForce AG participates in four upcoming international conferences in Q4
2016

Berlin, Germany and Nevada, USA, October 27, 2016 - MagForce AG (Frankfurt,
Entry Standard, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device
company in the field of nanomedicine focused on oncology, today announced
its participation in four upcoming scientific and investor conferences in
the fourth quarter 2016:

  - 13th AIO Autumn Convention - Oncology in Internal Medicine Working
    Group (AIO) - Update Medical Oncology

Date: November 17-19, 2016
Location: Berlin, Germany
Booth: No. 24, level 1

  - 21st Annual Scientific Meeting and Education Day of the Society for
    Neuro-Oncology (SNO)

Date: November 17-20, 2016
Location: Scottsdale, Arizona, USA
Presentation: "Inflammatory response after modified NanoTherm(R) and
radiotherapy of recurrent glioblastoma"
Presenter: Team of Prof. Dr. med. Walter Stummer, Director of the Clinic
for Neurosurgery, University Hospital Münster
Speaker: Dr. Dr. med. Oliver Grauer, Head of Neuro-Oncology Team,
University Hospital
Münster
Date of presentation: Friday, November 18, 2016; Poster session 19:00 MST

  - German Equity Forum

Date: November 21-23, 2016
Location: Frankfurt, Germany
Presentation: Ben J. Lipps, CEO of MagForce AG, Monday, November 21, 2016,
14:00 CET Room: Oslo

  - NOA Winter School 2016 - Neurological Working Group

Date: December 1-2, 2016
Location: Münster, Germany
Presentation: "Local Hyperthermia as an adjuvant for malignant glioblastoma
- NanoTherm and NanoPaste"
Speaker: Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical
Department, Clinic and Policlinic for Neurosurgery, University Hospital
Münster
Date of presentation: Thursday, December 1, 2016, 15:00 CET

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm(TM) therapy enables the
targeted treatment of solid tumors through the intratumoral generation of
heat via activation of superparamagnetic nanoparticles. Mithril Capital
Management, a growth-stage technology fund founded by Ajay Royan and Peter
Thiel, along with MagForce AG, are investors and strategic partners in
MagForce USA, Inc.

NanoTherm(TM), NanoPlan(R), and NanoActivator(R)  are components of the
therapy and have received EU-wide regulatory approval as medical devices
for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan, and
NanoActivator(R)  are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com  

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list



<pre>

For meeting arrangements or any further questions, please contact us at:

Patient Advocacy

Dr. Katarzyna Zarychta
+49 30 95 477 95-66
kzarychta@magforce.com

Medical Liaison

Dr. Ulrike Boettcher
+49 89 95 477 95-64
uboettcher@magforce.com

Media & Investors

Barbara v. Frankenberg
+49 30 30 83 80-77
bfrankenberg@magforce.com


</pre>

Disclaimer 

This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.






Contact:
   
Barbara von Frankenberg
Vice President
Communications & Investor Relations

T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com     


---------------------------------------------------------------------------

27.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

   Language:    English                                             
   Company:     MagForce AG                                         
                Max-Planck-Straße 3                                 
                12489 Berlin                                        
                Germany                                             
   Phone:       +49 (0)30 308 380 0                                 
   Fax:         +49 (0)30 308 380 99                                
   E-mail:      info@magforce.com                                   
   Internet:    www.magforce.com                                    
   ISIN:        DE000A0HGQF5                                        
   WKN:         A0HGQF                                              
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf,  
                Stuttgart, Tradegate Exchange; Open Market (Entry   
                Standard) in Frankfurt                              
 
 
   End of News    DGAP News Service  
---------------------------------------------------------------------------

514847 27.10.2016